Serum β-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report

David S Boss1, Hilary Glen2, Jos H Beijnen3,4, Daphne de Jong5, Jantien Wanders6, TR Jeffry Evans2, and Jan HM Schellens1,4

1Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 2Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; 3Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands; 4Science Faculty, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Utrecht University, Utrecht, The Netherlands; 5Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 6Eisai Limited, London, United Kingdom

ABSTRACT

Background. Elevated β-HCG serum levels are usually an indication of pregnancy or pregnancy-related disorders, but β-HCG can also be elevated in testis and germ cell tumors. HCG expression by osteosarcoma is a rare phenomenon, with a few documented cases. CA-125 is commonly used to monitor disease progression and treatment response in ovarian cancer. CA-125 expression in patients with osteosarcoma has not previously been documented.

Case report. Elevated β-HCG and CA-125 serum levels were observed in a female patient of 57 years of age with metastatic osteosarcoma during screening investigations prior to participation in a phase I clinical trial. Pregnancy was excluded. Immunohistochemical studies revealed the tumor to be the source of the elevated β-HCG serum levels. We found no CA-125 expression in tumor tissue. The patient was treated with E7080, a novel oral multi-targeted tyrosine kinase inhibitor. We measured serum β-HCG and CA-125 to monitor treatment response. She had a significant clinical and radiological response after two cycles of treatment, but developed progressive disease after the third cycle. The β-HCG serum levels seemed to better reflect her disease status than those of the other tumor marker, CA-125.

Conclusions. When elevated, β-HCG serum levels in patients with osteosarcoma might be used to monitor treatment. Treatment of advanced osteosarcoma with tyrosine kinase inhibitors, including E7080, warrants further investigation. Free full text available at www.tumoronline.it